Article
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2016
Modest D P, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal L F, Giessen-Jung C, Stahler A, Schmoll H J, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A
Abstract excerpt
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.